Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week Low – Time to Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX) hit a new 52-week low during trading on Tuesday . The stock traded as low as $11.43 and last traded at $11.65, with a volume of 251118 shares. The stock had previously closed at $11.60.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Stifel Nicolaus started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 target price for the company. Cantor Fitzgerald started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating on the stock. TD Cowen assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating for the company. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price target for the company. Finally, Morgan Stanley assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $43.75.

Bicara Therapeutics Stock Performance

The company’s 50-day simple moving average is $17.08.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. First Turn Management LLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at $14,324,000. Geode Capital Management LLC bought a new position in Bicara Therapeutics during the 3rd quarter worth approximately $1,239,000. Vestal Point Capital LP purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $10,825,000. FMR LLC bought a new stake in Bicara Therapeutics in the third quarter valued at approximately $57,913,000. Finally, Braidwell LP purchased a new stake in shares of Bicara Therapeutics during the third quarter valued at approximately $42,219,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.